Vycor Medical (VYCO) Common Equity (2010 - 2026)

Vycor Medical (VYCO) has 17 years of Common Equity data on file, last reported at -$4.2 million in Q1 2026.

• Common Equity for Q1 2026 came in at -$4.2 million, down 8.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.2 million (down 8.69% YoY), and the FY2025 annual result was -$4.1 million, down 10.75% from the prior year.
• Common Equity declined to -$4.2 million in Q1 2026 per VYCO's latest filing, from -$4.1 million in the prior quarter.
• Over five years, Common Equity peaked at -$2.6 million in Q1 2022 and troughed at -$4.2 million in Q1 2026.
• A 5-year average of -$3.4 million and a median of -$3.5 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity plunged 222.78% in 2022, then decreased 8.69% in 2026.
• A 5-year view of Common Equity shows it stood at -$2.9 million in 2022, then decreased by 13.08% to -$3.3 million in 2023, then retreated by 10.96% to -$3.7 million in 2024, then decreased by 10.75% to -$4.1 million in 2025, then retreated by 3.48% to -$4.2 million in 2026.
• Business Quant data shows VYCO's Common Equity at -$4.2 million in Q1 2026, -$4.1 million in Q4 2025, and -$4.0 million in Q3 2025.